Stockscreener 앱 받기
195.22
3.28%
6.20
시간 외 거래:
194.90
-0.32
-0.16%
전일 마감가:
$189.02
열려 있는:
$189.92
하루 거래량:
8.08M
Relative Volume:
1.28
시가총액:
$344.84B
수익:
$58.33B
순이익/손실:
$3.76B
주가수익비율:
92.96
EPS:
2.1
순현금흐름:
$15.39B
1주 성능:
+2.60%
1개월 성능:
+2.75%
6개월 성능:
+6.16%
1년 성능:
+2.90%
1일 변동 폭
$189.78
$197.06
1주일 범위
$187.62
$198.83
52주 변동 폭
$163.81
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today - AOL.com
AbbVie reports encouraging data from Upadacitinib trial for alopecia areata - MSN
AbbVie's Q2 2025 Earnings Call: Unpacking Contradictions in Skyrizi Growth, Inventory Strategies, and Market Dynamics - AInvest
AbbVie Shines in Earnings Call with Strong Growth - The Globe and Mail
Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more - Seeking Alpha
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer - The Globe and Mail
AbbVie Reports Strong Q2 2025 Financial Results - The Globe and Mail
AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume - AInvest
Why AbbVie Stock Flew Higher on Friday - Nasdaq
Major pharma company takes on Oregon 340B drug law - The Business Journals
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Why Is AbbVie Stock Gaining Friday?AbbVie (NYSE:ABBV) - Benzinga
Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining - Benzinga
Why AbbVie (ABBV) Stock Is Up Today - Yahoo Finance
AbbVie’s New Study on CLL Treatment: A Potential Game Changer? - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail
AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Call Transcript - MSN
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential - TipRanks
AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... - Yahoo.co
Stock Analysis | Abbvie OutlookA Mixed Technical Picture Amid Divergent Analyst Ratings - AInvest
AbbVie's Stock Dips 0.15% as Trading Volume Surges 108.9% to Rank 50th in Market Activity Behind Strong Q2 Earnings - AInvest
M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics - TipRanks
AbbVie Stock Pops After Earnings Beat and Guidance Raised - MSN
Why AbbVie Stock Slumped Today - Yahoo Finance
Market Today: Meta and Microsoft Lead AI Surge, AbbVie Eyes Acquisition - GuruFocus
AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength - insights.citeline.com
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A - BioPharma Dive
Research Alert: CFRA Retains Buy Opinion On Shares Of Abbvie Inc. - 富途牛牛
CoreWeave, Arm Holdings, AbbVie: Trending Tickers - Yahoo Finance
AbbVie Earnings: Continued Impressive Demand for Skyrizi, Neuroscience Portfolio Support Growth - Morningstar
AbbVie: Q2 Earnings Snapshot - The Washington Post
Trump demands largest pharma companies slash US drug prices - Yahoo Finance
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow - MarketBeat
Earnings call transcript: AbbVie Q2 2025 sees stock surge on earnings beat - Investing.com Canada
AbbVie sees no outsized tariff exposure, boosts profit forecast - Reuters
AbbVie Lifts Forecasts As Immunology Drugs Drive Growth - Finimize
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks - Seeking Alpha
Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook - Yahoo Finance
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View - Yahoo Finance
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer? - The Globe and Mail
AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier - Yahoo Finance
AbbVie Stock Pops After Earnings. What’s Driving Shares Higher. - Barron's
AbbVie Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AbbVie raises guidance as key drugs and pipeline deals boost growth - Crain's Chicago Business
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AbbVie 2nd-quarter beats expectations - The Pharma Letter
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg.com
AbbVie lifts profit forecast on strong demand for newer immunology drugs - Reuters
Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts - The Wall Street Journal
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates - Yahoo.co
Is Now the Time to Buy AbbVie Ahead of a Pivotal Transition? - AInvest
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.57%
자본화:
|
볼륨(24시간):